.svg)
Coaching and lifestyle education are more than optional “extras” to GLP-1 therapy; they're what help make results last.
GLP-1 medications like semaglutide and tirzepatide can change what’s possible in metabolic health. At Shed, we've seen members experience real transformation, not just in how their body looks, but in how they feel about food and themselves. We believe in these medications. And because we believe in them, we want you to understand exactly what they do, what they don't do, and why the support around the medication matters just as much as the medication itself.
This is a preparedness blog grounded in science and built from hundreds of real coaching conversations.
How GLP-1 medications affect the brain’s reward system
Most people know GLP-1 medications suppress appetite and slow digestion. What most people don't know is that these medications also act on the brain's reward system, the same circuitry that drives motivation, pleasure, and habit.
When my clients describe "food noise" going quiet, that's not just hunger disappearing. It's the brain's “wanting” signal turning down. The constant mental pull toward food, the thinking about it, planning for it, reaching for it out of habit or emotion—that's a dopamine-driven experience. And GLP-1 medications can dial that down.
This may be why early research is showing that some people on these medications are also drinking less alcohol and finding it easier to quit smoking. It's the same brain pathway. The medication doesn't discriminate; it quiets reward-seeking broadly, not just around food.
For many, that's a relief, and part of why they might seek out a GLP-1 as a tool. But it's worth noting that some members notice a broader dulling and less joy in food, and sometimes less engagement in other areas of life that once felt pleasurable. Researchers call this hedonic blunting. It doesn't happen to everyone, but being aware that it can happen means you're not caught off guard.
Why the end of the week on a GLP-1 can feel harder
Because most GLP-1 injections are dosed weekly, the experience isn't perfectly consistent across seven days. As medication levels naturally shift toward the end of the cycle, some members notice cravings returning or food becoming louder in their mind again.
If no one has prepared you for this, it's easy to read it as losing control, failure, or that the medication is not working. But you are not broken, and neither is the GLP-1. It's a predictable pharmacological pattern and one that is completely normal.
This is one of the most valuable things a coach can offer: helping you understand your own weekly rhythm, recognize what's biological versus behavioral or emotional, and build habits that hold even when the medication isn't doing all the heavy lifting.
Guilt is not a healthy strategy. Curiosity is.
Here's something I say often to my clients at Shed, and mean it as both a coaching principle and a biological statement: guilt holds no healthy merit in a health journey. Curiosity does.
When someone on a GLP-1 medication eats a piece of chocolate or has a bigger meal than planned, the worst thing that can happen next is shame. Not because feelings don't matter—they do, and offer useful feedback—but because shame triggers a stress response in the body. Stress hormones rise. And elevated stress hormones drive cravings for exactly the kinds of foods we're trying to move away from.
In other words, guilt is metabolically counterproductive. It can turn one imperfect moment into a full spiral. Not through lack of willpower, but through a stress-driven biological chain reaction.
At Shed, we believe in the 80/20 rule: eat in a way that supports your health most of the time, and give yourself genuine permission for flexibility, indulgence, and unpredictability for the rest. That permission isn't a weakness. It's actually what makes the 80% stick.
Behavior change research makes a clear distinction between a lapse and a relapse. A lapse is a moment, one harder day, one unplanned meal. Lapses are normal, even expected. A relapse is a return to an old pattern. What turns a lapse into a relapse isn't the food. It's often the shame and choices that follow eating.
Our coaches are trained to meet those moments with curiosity instead of correction. What was happening that day? Where were you in your dosing cycle? What did you actually need? This reframing helps you become more aware of what’s happening in your body, and why, so you are better equipped to notice patterns and break them.
How to know if your GLP-1 dose is too high
This needs to be said plainly: nausea and inability to eat for most of the week are signs that your dose may be too high, not that your medication is working harder. It may be normal to feel nauseous or have little appetite within 24 hours of a dose or titration, but it should not be constant.
The clinical goal of GLP-1 therapy has always been to find the effective dose—the dose that produces real metabolic benefit without making a person unable to nourish themselves. When doses get pushed beyond that, the consequences are predictable: protein deficiency, muscle loss, micronutrient depletion, fatigue, hair loss, and disrupted electrolytes.
Therapeutic dosing should feel like this: food noise quiets, you feel satisfied with less, meals feel manageable, energy stays stable, and you are still able to eat enough to nourish your body. If the experience is primarily nausea and avoidance, that's a conversation to have with the prescriber, not a badge of progress.
Thinness and health are not the same thing. A person can be smaller and more metabolically fragile. Body composition, energy, lab markers, and how you feel day-to-day tell a more complete story than a number on a scale.
Building habits that last beyond the medication
Here is the most important thing we want you to carry through your time on a GLP-1: the medication creates the conditions for change. It doesn't create the change itself.
When food noise quiets and old patterns loosen their grip, that's a window, often one people haven't had before. Research consistently shows that when people stop GLP-1 medications without doing the behavioral work, the patterns return. Not because they failed, but because the medication was doing the holding, and nothing was built to hold it instead.
The habits, the self-awareness, the new relationship with food, the understanding of your own triggers—that's what lasts. Building it is the work. And the window of opportunity the medication creates is the best time to do it.
This is why Shed exists. Not to add coaching on the side, but to be the structure inside the window so that when the window changes, you're not starting over.
How Shed supports you
Our approach rests on pillars of treatment, nutrition, movement, sleep, and social-emotional health.
Our coaches bring expertise in facilitating lifestyle factors into your routine. They help you understand your complete wellness journey at Shed, navigating between what's pharmacological and what's behavioral.
In addition, our Shed Community is built specifically for people on GLP-1 medications. It holds what coaching and education alone can’t: real people going through the same thing, in real time, with coaches present. Shame thrives in isolation. Curiosity thrives in community.
Feeling joy around food is not the enemy. Food is nourishment, culture, celebration, and connection, and you are allowed to experience it that way. Using food to cope is the pattern worth examining. Not with guilt. With genuine curiosity about what you need and what might serve you better.
Shed is here to help you navigate all of it. Visit tryshed.com today to learn more.
FAQs
What is hedonic blunting?
Hedonic blunting is a reduction in pleasure or enjoyment that some people experience on GLP-1 medications. Because these drugs act on the brain’s circuitry broadly, not just around food, some people notice less joy from eating and occasionally less engagement in other activities they once found pleasurable.
Does semaglutide affect dopamine?
Yes. Semaglutide and other GLP-1 medications act on the brain’s reward system, not just hunger signals. They reduce dopamine-driven “wanting,” which is the mental pull toward food, alcohol, and other reward-seeking behaviors. This is why many people on GLP-1s report that food noise quiets, cravings decrease, and habits that once felt compulsive become easier to step back from.
Why do my cravings come back at the end of the week on a GLP-1?
GLP-1 injections are dosed weekly, and medication levels naturally taper toward the end of the dosing cycle. As levels shift, some people notice food noise returning or cravings feeling louder. This is a normal, predictable pharmacological pattern, not a sign that the medication isn’t working.
Is nausea on a GLP-1 medication normal?
Mild nausea within 24 hours of a dose or dose increase is common, especially early in treatment. However, if nausea is persistent, this can mean the dose is too high. Communicate all GLP-1 side effects with your provider so they can prescribe the right titration schedule for you.
Do I need a health coach with a GLP-1 prescription?
Health coaching isn’t a required part of GLP-1 therapy, but research and clinical experience consistently show that behavioral support helps improve and sustain outcomes. Because GLP-1s are designed to suppress appetite, they can get you started on building healthier habits around food, but they don’t create lasting habits on their own. Health coaching can help you understand what’s pharmacological versus emotional and develop habits that last beyond the medication. Without this type of support, many people find themselves back where they started when they taper off the medication or stop completely.
What should eating feel like on a GLP-1 medication?
At the right dose, you should feel satisfied with smaller portions and energy levels should stay relatively stable. If nausea or other side effects dominate your experience, talk to your provider about potentially altering your dose or switching to a different medication.
References
Kooij et al. (2024). GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neuroscience Applied, 3, 103925. https://pmc.ncbi.nlm.nih.gov/articles/PMC12244221/
Merkel et al. (2025). An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Cited in: Curbing the appetites and restoring the capacity for satisfaction. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12244148/
Hendershot et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/
Lähteenvuo et al. (2024). Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry, 82(1), 94–98. https://pmc.ncbi.nlm.nih.gov/articles/PMC11561716/
Sa et al. (2026). Psychiatric effects of GLP-1 receptor agonists: a systematic review of emerging evidence. Diabetes, Obesity and Metabolism, 28(1), 50–59. https://pmc.ncbi.nlm.nih.gov/articles/PMC12673456/
Iyer et al. (2025). Neurobiological mechanisms and therapeutic potential of GLP-1 receptor agonists in binge eating disorder: a narrative review. MDPI International Journal of Molecular Sciences, 26(22), 10974. https://www.mdpi.com/1422-0067/26/22/10974
Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
Rubino et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414–1425. https://pubmed.ncbi.nlm.nih.gov/33755728/
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine / The Lancet. (2025). https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00614-5/fulltext
Chang et al. (2022). Stress-induced alterations in HPA-axis reactivity and mesolimbic reward activation in individuals with emotional eating. Appetite, 168, 105707. https://pmc.ncbi.nlm.nih.gov/articles/PMC8671188/
Smith et al. (2025). Hunger games: a modern battle between stress and appetite. Journal of Neurochemistry. https://onlinelibrary.wiley.com/doi/10.1111/jnc.70006
Knezevic et al. (2024). Glucocorticoids and HPA axis regulation in the stress–obesity connection. Clinical Obesity, Wiley/World Obesity Federation. https://pmc.ncbi.nlm.nih.gov/articles/PMC11907100/
This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting or changing any medication.
Compounded medications are not FDA-approved for safety, effectiveness, or quality. They are prepared by a licensed pharmacy based on a provider's prescription.
Medication is prescribed only after consultation with a licensed provider to determine appropriateness. Individual results may vary.
